WHO WE ARE
IRBM is a leading research organization with extensive experience in transforming early-stage science into advanced drug discovery programs. Specializing in cancer, neurological disorders, infection, and rare diseases, we offer both comprehensive and specialized services throughout the drug discovery process.
Founded in 2000 as the Italian branch of Merck & Co’s Research Laboratories, and independent since 2010, our notable achievements include the discovery of three marketed therapeutics. We partner with top pharmaceutical firms, biotech companies, and prominent foundations, including MD Anderson Cancer Center and CHDI Foundation. In 2022, we joined the National Cancer Institute’s Next Program’s Chemical Biology Consortium to advance therapeutic oncology solutions.
Our infectious disease research, notably in Hepatitis B, has earned substantial European Investment Bank funding and successful out-licensing of our innovations, developed with key Italian partners like the National Institute of Molecular Genetics and San Raffaele Hospital.
WHAT WE DO
Science is our cornerstone. We leverage our shared enthusiasm for science and our dedication to excellence to advance your drug discovery projects. Together, we develop innovative and more effective therapeutics that will improve patients’ quality of life worldwide.
Thanks to our broad expertise, your program can benefit from being developed at IRBM as an integrated project, or through smaller, standalone projects. In the case of integrated programs, we will build clear, actionable go/no-go decision points, and employ a first-to-fail approach to ensure your resources are efficiently managed.
Every day, our passion drives us to continue to learn, develop, and stay at the forefront of science, technology, and innovation.